FSD Pharma - Prakiraan wutah bathi resik saben saham kanggo taun ngarep HUGE

FSD Pharma Inc. (HUGE) brings together leading neurologists developing innovative brain medications. The projected EPS growth rate confirms the asset's momentum, where 0.00 indicates the current level. The company competes for capital with small pre-commercial biotech startups. The R&D model assumes a cash burn until formulas are patented, which will ensure high margins without capital expenditures.

FSD Pharma (HUGE): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 04.07.2022 nganti 15.08.2024

Ringkesan rincian data analitis fsdpharma.com (HUGE)

- rega lan prakiraan konsensus rega:

Bagan rega FSD Pharma Inc.|HUGE - Konsensus nilai wajar

- rincian nilai pasar emiten:

Nilai pasar FSD Pharma|HUGE - Total Nilai Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Siji Saham FSD Pharma|HUGE - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku fsdpharma.com|HUGE - Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

- data bathi resik lan rasio valuasi:

HUGE - Bathi perusahaan|Bathi mangsa ngarep FSD Pharma Inc.|HUGE - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep FSD Pharma Inc.|HUGE - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA FSD Pharma|HUGE - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) FSD Pharma|HUGE - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan fsdpharma.com|HUGE - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep FSD Pharma Inc.

- statistik dodolan lan pendapatan perusahaan:

HUGE - Dodolan perusahaan|Prakiraan volume dodolan FSD Pharma|HUGE - Multiplikator P/S|Multiplikator forward rega marang pendapatan FSD Pharma

Analisis fundamental perusahaan:FSD Pharma Inc., HUGE

This indicator measures the consensus forecast of professional analysts regarding the change in earnings per share (EPS) for the coming year, reflecting market expectations for future business profitability. The current value of 0.00 and the trend of EPS growth forecasts are critical for FSD Pharma Inc. (HUGE), as the potential commercialization of patented brain treatment drugs promises a sharp surge in margins.

Karo sapa FSD Pharma Inc. saingan